Latest Insider Transactions at Pliant Therapeutics, Inc. (PLRX)
This section provides a real-time view of insider transactions for Pliant Therapeutics, Inc. (PLRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of PLIANT THERAPEUTICS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of PLIANT THERAPEUTICS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 29
2023
|
Bernard Coulie President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
68,749
+18.15%
|
-
|
|
Feb 03
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-2.98%
|
$495,000
$33.72 P/Share
|
|
Feb 03
2023
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+5.55%
|
$90,000
$6.22 P/Share
|
|
Feb 02
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-2.96%
|
$510,000
$34.55 P/Share
|
|
Feb 02
2023
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+5.55%
|
$90,000
$6.22 P/Share
|
|
Feb 01
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-1.99%
|
$510,000
$34.83 P/Share
|
|
Feb 01
2023
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+5.55%
|
$90,000
$6.22 P/Share
|
|
Jan 31
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-5.88%
|
$510,000
$34.92 P/Share
|
|
Jan 31
2023
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+2.88%
|
$60,000
$4.15 P/Share
|
|
Jan 30
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-2.97%
|
$510,000
$34.32 P/Share
|
|
Jan 30
2023
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+5.55%
|
$30,000
$2.08 P/Share
|
|
Jan 27
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Indirect |
10,000
-1.19%
|
$350,000
$35.87 P/Share
|
|
Jan 27
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-2.98%
|
$525,000
$35.74 P/Share
|
|
Jan 27
2023
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+5.55%
|
$30,000
$2.08 P/Share
|
|
Jan 26
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Indirect |
15,000
-3.45%
|
$525,000
$35.09 P/Share
|
|
Jan 26
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-5.88%
|
$525,000
$35.29 P/Share
|
|
Jan 26
2023
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+5.55%
|
$30,000
$2.08 P/Share
|
|
Jan 25
2023
|
Bernard Coulie President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
146,300
+37.86%
|
-
|
|
Jan 25
2023
|
Eric Lefebvre Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
57,000
+29.85%
|
-
|
|
Jan 25
2023
|
Mike Ouimette General Counsel & Corp. Sec'y |
BUY
Grant, award, or other acquisition
|
Direct |
39,000
+46.46%
|
-
|
|
Jan 25
2023
|
Hans Hull Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,000
+21.93%
|
-
|
|
Jan 25
2023
|
Keith Lamont Cummings Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,000
+28.06%
|
-
|
|
Jan 25
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-7.0%
|
$480,000
$32.85 P/Share
|
|
Jan 25
2023
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+12.12%
|
$30,000
$2.08 P/Share
|
|
Jan 24
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-13.79%
|
$450,000
$30.89 P/Share
|
|
Jan 24
2023
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+12.12%
|
$30,000
$2.08 P/Share
|
|
Jan 23
2023
|
Keith Lamont Cummings Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
30,000
-26.22%
|
$1,050,000
$35.0 P/Share
|
|
Jan 23
2023
|
Keith Lamont Cummings Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+12.34%
|
$120,000
$4.15 P/Share
|
|
Jan 23
2023
|
Eric Lefebvre Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
67,500
-46.74%
|
$2,295,000
$34.48 P/Share
|
|
Jan 23
2023
|
Mike Ouimette General Counsel & Corp. Sec'y |
SELL
Open market or private sale
|
Direct |
20,000
-77.08%
|
$680,000
$34.19 P/Share
|
|
Jan 23
2023
|
Mike Ouimette General Counsel & Corp. Sec'y |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+33.18%
|
$360,000
$18.09 P/Share
|
|
Jan 23
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Indirect |
15,000
-3.34%
|
$525,000
$35.0 P/Share
|
|
Jan 23
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-7.12%
|
$510,000
$34.32 P/Share
|
|
Jan 23
2023
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+12.12%
|
$30,000
$2.08 P/Share
|
|
Jan 09
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
5,000
-5.06%
|
$95,000
$19.17 P/Share
|
|
Jan 09
2023
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.82%
|
$10,000
$2.08 P/Share
|
|
Jan 06
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-13.79%
|
$285,000
$19.04 P/Share
|
|
Jan 06
2023
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+12.12%
|
$30,000
$2.08 P/Share
|
|
Jan 04
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-13.79%
|
$285,000
$19.06 P/Share
|
|
Jan 04
2023
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+12.12%
|
$30,000
$2.08 P/Share
|
|
Jan 03
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-13.79%
|
$285,000
$19.33 P/Share
|
|
Jan 03
2023
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+12.12%
|
$30,000
$2.08 P/Share
|
|
Dec 22
2022
|
Keith Lamont Cummings Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+4.52%
|
$8,000
$2.08 P/Share
|
|
Dec 22
2022
|
Mike Ouimette General Counsel & Corp. Sec'y |
SELL
Open market or private sale
|
Direct |
2,928
-32.99%
|
$55,632
$19.38 P/Share
|
|
Dec 20
2022
|
Hans Hull Chief Business Officer |
SELL
Open market or private sale
|
Direct |
8,748
-5.95%
|
$166,212
$19.1 P/Share
|
|
Dec 20
2022
|
Mike Ouimette General Counsel & Corp. Sec'y |
SELL
Open market or private sale
|
Direct |
4,719
-34.71%
|
$89,661
$19.1 P/Share
|
|
Dec 20
2022
|
Eric Lefebvre Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,887
-7.01%
|
$206,853
$19.1 P/Share
|
|
Dec 20
2022
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
34,212
-26.72%
|
$650,028
$19.1 P/Share
|
|
Dec 20
2022
|
Keith Lamont Cummings Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,643
-10.71%
|
$183,217
$19.1 P/Share
|
|
Dec 19
2022
|
Hans Hull Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,578
+10.68%
|
-
|